## VENLAFAXINE HCI EFFEXOR XR RIGHS REAST


Brief Summary

The Summary

The

of placetic in depression their included massa, aromatis, by mouth, dizzmes, incomis, and sommelmer, in U.S. places—subtisted depression their probled hyperferram, during problems, there is no controlled depression their problems. As the problems of the places of the





the ability to achieve recovery.1

Visit us at www.EFFEXORXR.com

Please see brief summary of Prescribing Information on adjacent page.

## The efficacy and safety of EFFEXOR XR for pediatric use have not been established.

EFFEXOR XR is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). EFFEXOR XR should not be used in combination with an MAOI or within at least 14 days of discontinuing treatment with an MAOI; at least 7 days should be allowed after stopping EFFEXOR XR before starting an MAOI.

The most common adverse events reported in EFFEXOR XR placebo-controlled depression trials (incidence ≥10% and ≥2× that of placebo) were nausea, dizziness, somnolence,

Reference: 1. Data on file, Wyeth-Ayerst Laboratories, Philadelphia, Pa.

abnormal ejaculation, sweating, dry mouth, and nervousness; and in GAD trials were nausea, dry mouth, insomnia, abnormal ejaculation, anorexia, constipation, nervousness, and sweating.

Treatment with venlafaxine is associated with sustained increases in blood pressure (BP) in some patients. Three percent of EFFEXOR XR patients in depression studies (doses of 75 to 375 mg/day) and 0.4% in GAD studies (doses of 75 to 225 mg/day) had sustained BP elevations. Less than 1% discontinued treatment because of elevated BP. Regular BP monitoring is recommended.